Transgene Sa Stock Analysis

Transgene Pink Sheet Analysis Notes

The company has price-to-book ratio of 0.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transgene SA recorded a loss per share of 0.23. The entity had not issued any dividends in recent years. Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.The quote for Transgene SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Transgene SA contact Hedi Brahim at 33 3 88 27 91 00 or learn more at https://www.transgene.fr.

Transgene SA Investment Alerts

Transgene Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 212.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Transgene's market, we take the total number of its shares issued and multiply it by Transgene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Transgene Profitablity

The company has Profit Margin (PM) of (1.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39.

Technical Drivers

In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Transgene SA, as well as the relationship between them.

Transgene SA Price Movement Analysis

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Transgene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Transgene shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Transgene. By using and applying Transgene Pink Sheet analysis, traders can create a robust methodology for identifying Transgene entry and exit points for their positions.

When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.